Sign in
CompletedNo phase

Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery

Key facts

Who runs it
Dong-Xin Wang
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
504 people enrolled
Started
16 Apr 2019
Ended
18 May 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dexmedetomidine
  • Placebo
Record updated
27 April 2026

Who can take part

Age
60 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age ≥60 years but <90 years
  • Scheduled to undergo cardiac surgery with cardiopulmonary bypass under general anesthesia
  • Expected to stay in the intensive care unit (ICU) for at least 1 night after surgery

Who cannot take part

  • Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or the snoring, tiredness, observed apnea, high blood pressure-body mass index, age, neck circumference and gender [STOP-Bang] questionnaires ≥3)
  • Severe renal dysfunction (requirement of renal replacement therapy) before surgery
  • Current treatment with dexmedetomidine or clonidine
  • Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis
  • Inability to communicate during the preoperative period because of coma, profound dementia or language barrier
  • Preoperative sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree atrioventricular block or above without pacemaker
  • Patients who meet any of the following criteria will be excluded
  • Refuse to participate in the study
  • Severe hepatic dysfunction (Child-Pugh class C)
  • Presence of delirium (diagnosed by the Confusion Assessment Method [CAM]/CAM for the Intensive Care Unit [CAM-ICU])

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Delirium is an acutely occurred and fluctuating cerebral dysfunction characterized with inattention, altered consciousness, cognitive decline and/or abnormal perception. It is common in the elderly after cardiac surgery and is associated with worse outcomes. Causes leading to delirium are multifactorial but sleep disturbances remains an important one. In previous studies, sedative-dose dexmedetomidine improves sleep quality in ICU patients with mechanical ventilation; and low-dose dexmedetomidine improves sleep quality in postoperative patients without mechanical ventilation. In recent studies of elderly after noncardiac surgery, night-time infusion of low-dose dexmedetomidine reduces delirium and improves 2-year survival. The investigators hypothesize that, for elderly patients after cardiac surgery, night-time infusion of dexmedetomidine may also improve sleep quality, reduce delirium development and improve 2-year survival.

The 2 groups in the trial

  • Dexmedetomidine groupTreatment being tested

    Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.

    Treatment: Dexmedetomidine

  • Placebo groupPlacebo, for comparison

    Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effect of Low-dose Dexmedetomidine on Postoperative Delirium in Patients After Cardiac Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial
Record updated
27 April 2026